Gelonghui Reports CMS’ Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets
SHENZHEN, CHINA, Dec 19, 2022 - (ACN Newswire via SEAPRWire.com) - Gelonghui released a Press Release on "China Medical System Holdings Limited's innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets ('the Product') has obtained positive results for its Phase III clinical trial in China."This is another breakthrough for the Product after China Medical System Holdings Limited ("CMS" or the "Group") had efficiently completed the enrollment of all 1,802 subjects for its China Phase III Clinical Trial in July this year, of which only 6 months (including the Spring Festival Holiday) was taken. The Group will actively move forward the Product's new drug application (NDA) in China.In this China Phase III clinical trial, Methylthioninium Chloride Enteric-coated Sustained-release Tablets was compared to placebo with the purpose of assessing its safety and efficacy in the improvement of histologically confirmed non-polypoid colorectal lesions in subjects undergoing screening or surveillance colonoscopy for colorectal cancer. The research was led by Beijing Friendship Hospital, Capital Medical University and conducted in 22 sites nationwide. In total, 1802 subj...
